Sintilimab, a PD-1 Inhibitor, Completely Reversed Rarely Refractory Hypofibrinogenemia in a Gastric Cancer Patient: A Case Report and Review of the Literature.

Ma, Shuzhen; Dang, Qi; Yang, Yali; Liu, Yongliang; Sun, Yuping; Sun, Meili

Ma, Shuzhen; Dang, Qi; Yang, Yali; Liu, Yongliang; Sun, Yuping; Sun, Meili.

Afiliação

Ma S; Department of Oncology, Jinan Central Hospital Affiliated to Shandong University, Jinan, China.
Dang Q; Department of Oncology, Central Hospital Affiliated to Shandong First Medical University, Jinan, China.
Yang Y; Department of Oncology, Jinan Central Hospital Affiliated to Shandong University, Jinan, China.
Liu Y; Department of Oncology, Central Hospital Affiliated to Shandong First Medical University, Jinan, China.
Sun Y; Department of Oncology, Central Hospital Affiliated to Shandong First Medical University, Jinan, China.
Sun M; Department of Oncology, Jinan Central Hospital Affiliated to Shandong University, Jinan, China.

Front Oncol ; 10: 526096, 2020.

Article em En | MEDLINE | ID: mdl-33194584